| Drug General Information |
| Drug ID |
D02XKK
|
| Former ID |
DIB016144
|
| Drug Name |
FRM-0962
|
| Indication |
Alzheimer disease [ICD9: 331; ICD10:G30]
|
Phase 2 |
[1]
|
|---|
| Company |
Forum pharmaceuticals
|
| Target and Pathway |
| Target(s) |
Amyloid beta A4 protein |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
Notch signaling pathway
|
|
Alzheimer's disease
|
|
Reactome
|
Nuclear signaling by ERBB4
|
|
Degradation of the extracellular matrix
|
|
Regulated proteolysis of p75NTR
|
|
NRIF signals cell death from the nucleus
|
|
Activated NOTCH1 Transmits Signal to the Nucleus
|
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
|
EPH-ephrin mediated repulsion of cells
|
|
WikiPathways
|
Notch Signaling Pathway
|
|
Signaling by ERBB4
|
|
Signaling by NOTCH3
|
|
Signaling by NOTCH4
|
|
Signaling by NOTCH1
|
|
Signaling by NOTCH2
|
|
Notch Signaling Pathway
|
|
Alzheimers Disease
|
|
Signalling by NGF
|
| References |
| REF 1 | Clinical pipeline report, company report or official report of Forum pharmaceuticals. |
|---|
| REF 2 | Gamma-secretase. SciBX 7(40); doi:10.1038/scibx.2014.1175. Oct. 16 2014 |
|---|
